- Home
- ISTR vs TVRD Comparison
ISTR vs TVRD Comparison
Compare ISTR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ISTR | TVRD |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.3M | 246.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ISTR | TVRD |
|---|---|---|
| Price | $26.03 | $4.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $29.00 | ★ $51.67 |
| AVG Volume (30 Days) | 27.5K | ★ 138.9K |
| Earning Date | 01-22-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ 24.14 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $93,426,000.00 | N/A |
| Revenue This Year | $7.24 | N/A |
| Revenue Next Year | $70.19 | N/A |
| P/E Ratio | $11.71 | ★ N/A |
| Revenue Growth | ★ 12.93 | N/A |
| 52 Week Low | $15.39 | $3.74 |
| 52 Week High | $26.33 | $43.65 |
Technical Indicators
Market Signals| Indicator | ISTR | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 73.01 | 29.49 |
| Support Level | $24.62 | $3.74 |
| Resistance Level | $26.33 | $4.18 |
| Average True Range (ATR) | 0.58 | 0.27 |
| MACD | 0.18 | 0.69 |
| Stochastic Oscillator | 89.35 | 69.70 |
Price Performance
Historical ComparisonAbout ISTR Investar Holding Corporation
Investar Holding Corp is a U.S.-based financial holding company. Through its subsidiaries, it offers a variety of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses, as well as loans to individuals. It has business operations spread across the United States and serves its customers through several service branches. The bank also offers cashiers' checks, direct deposit of payroll and Social Security checks, night depository, bank-by-mail, automated teller machines with deposit automation, and debit cards.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.